Johnson & Johnson - JNJ STOCK NEWS

Johnson & Johnson (NYSE: JNJ) will participate in the Cowen 42nd Annual Health Care Virtual Conference on March 7, 2022, at 9:10 a.m. (Eastern Time). Mathai Mammen, Executive VP of Pharmaceuticals R&D, will represent the company. Investors and interested parties can access the conference call via the Johnson & Johnson website. A webcast and podcast replay will be available approximately 48 hours after the live event.

Johnson & Johnson (NYSE: JNJ) will participate in Citi's 2022 Virtual Healthcare Conference on February 23, 2022. The session will feature Ashley McEvoy, Executive Vice President, Worldwide Chairman, Medical Devices, presenting at 11:00 a.m. ET. Interested investors can access the conference via the Johnson & Johnson website. Following the live event, a webcast and podcast replay will be available approximately 48 hours later.

Johnson & Johnson (NYSE: JNJ) reported a robust performance for Q4 and full-year 2021. Reported sales reached $24.8 billion in Q4, a 10.4% increase, and $93.8 billion for the year, up 13.6%. Net earnings surged by 172.5% in Q4 to $4.7 billion, while full-year net earnings rose 41.9% to $20.9 billion. Adjusted operational sales growth was notable in Pharmaceuticals (13.6%) and Medical Devices (16.8%), despite supply constraints in Consumer Health. New product approvals and a planned separation of the Consumer Health business were also highlighted as key strategic moves for future growth.

On January 6, 2022, Johnson & Johnson (NYSE: JNJ) released findings from the largest study on COVID-19 vaccine durability in the U.S., highlighting that a single dose of their vaccine provides long-term protection for up to six months. The study, conducted with leading institutions, confirmed an approximately 80% effectiveness against hospitalizations. Notable results included no waning protection against ICU admissions and a modest increase in breakthrough infections after month four. This research positions the Johnson & Johnson vaccine as a viable option amid evolving COVID-19 variants.

Johnson & Johnson (NYSE: JNJ) has declared a cash dividend of $1.06 per share for the first quarter of 2022. This dividend payment is scheduled for March 8, 2022, to shareholders on record as of February 22, 2022, with an ex-dividend date of February 18, 2022. The announcement underscores the company's commitment to returning value to its shareholders while continuing its mission to improve health outcomes globally.

Johnson & Johnson (NYSE: JNJ) reported positive preliminary results from the South African Phase 3b Sisonke study, indicating an 85% effectiveness of its COVID-19 vaccine booster against hospitalization during the Omicron variant surge. The study involved healthcare workers and revealed that vaccine effectiveness increased over time post-boost. Additionally, a separate analysis showed that a heterologous booster regimen significantly enhanced immune responses compared to a homologous booster. These findings underscore the robustness of the Johnson & Johnson vaccine amidst evolving COVID-19 variants.

The CHMP of the EMA issued a Positive Opinion for Johnson & Johnson's COVID-19 vaccine booster, recommending it for adults 18+ at least two months post-initial vaccination. The booster increased protection to 75% against symptomatic COVID-19 and demonstrated 100% protection against severe cases, with data from the Phase 3 ENSEMBLE 2 study. The vaccine was generally well-tolerated, showing no new safety concerns. The recommendation supports its use as a 'mix and match' booster.

Johnson & Johnson (NYSE: JNJ) will hold a conference call on January 25, 2022, at 8:30 a.m. Eastern Time to discuss its fourth-quarter results. The call will feature key executives, including Joaquin Duato, the incoming CEO. Investors can access the call via the company's website and by phone. A replay will be available until February 8, 2022. The earnings report will be released at approximately 6:45 a.m. Eastern Time on the same day. For future events, please visit Johnson & Johnson's investor relations page.

Johnson & Johnson (NYSE: JNJ) received interim recommendations from the WHO's Strategic Advisory Group of Experts (SAGE) supporting its COVID-19 vaccine as a booster shot for individuals 18 and older, to be given 2 to 6 months post the primary vaccination. The booster enhances protection against symptomatic infections and severe disease. The recommendations are based on data from clinical trials and Phase 3 studies. The company is committed to delivering up to 900 million doses to the African Union and COVAX by 2022, ensuring accessibility amid the pandemic.